Achieving PSA

MONDAY, Aug. 10, 2026-- For patients with metastatic castration-sensitive prostate cancer (mCSPC), achieving a prostate-specific antigen (PSA) level of <0.2 ng/mL within nine months of initiating treatment is associated with improved overall...